Byers LA

Chugh R

Curtin NJ

de Bono J

Glaspy J

Henshaw JW

Herriott A

Heymach J

Kaye S

Mina L

Patterson M

Rafii S

Ramanathan RK

Sachdev J

Smith DC

Wainberg ZA

\ua9 2017 AACR. Talazoparib inhibits PARP catalytic activity, trapping PARP1 on damaged DNA and causing cell death in BRCA1/2-mutated cells. We evaluated talazoparib therapy in this two-part, phase I, first-in-human trial. Antitumor activity, MTD, pharmacokinetics, and pharmacodynamics of once-daily talazoparib were determined in an open-label, multicenter, dose-escalation study (NCT01286987). The MTD was 1.0 mg/day, with an elimination half-life of 50 hours. Treatmentrelated adverse events included fatigue (26/71 patients; 37%) and anemia (25/71 patients; 35%). Grade 3 to 4 adverse events included anemia (17/71 patients; 24%) and thrombocytopenia (13/71 patients; 18%). Sustained PARP inhibition was observed at doses ≥0.60 mg/day. At 1.0 mg/day, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients with BRCA mutation- associated breast and ovarian cancers, respectively, and in patients with pancreatic and small cell lung cancer. Talazoparib demonstrated single-agent antitumor activity and was well tolerated in patients at the recommended dose of 1.0 mg/day. SIGNIFICANCE: In this clinical trial, we show that talazoparib has single-agent antitumor activity and a tolerable safety profile. At its recommended phase II dose of 1.0 mg/day, confirmed responses were observed in patients with BRCA mutation-associated breast and ovarian cancers and in patients with pancreatic and small cell lung cancer

Newcastle University E-Prints

Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline <em>BRCA1/2</em> mutations and selected sporadic cancers

Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline <em>BRCA1/2</em> mutations and selected sporadic cancers

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints